MedTrace Logo

A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum

NCT03436615 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 256

Last updated 2023-05-06

Study results available
· View outcomes & findings →

Summary

This is a phase 2 multi-center, randomized, double-blind, vehicle-controlled ascending dose study to be conducted in non-immunocompromised subjects with molluscum contagiosum.

Conditions

  • Molluscum Contagiosum

Interventions

DRUG

SB206 4%

Twice daily

DRUG

SB206 8%

Twice daily

DRUG

SB206 12%

Once or twice daily

DRUG

Placebo

Once or twice daily

Sponsors & Collaborators

  • Premier Research Group plc

    collaborator UNKNOWN

  • Novan, Inc.

    lead INDUSTRY

Principal Investigators

  • Tomoko Maeda-Chubachi, MD · Novan, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-01-24
Primary Completion
2018-11-03
Completion
2018-11-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03436615 on ClinicalTrials.gov